Scherpereel A, Grigoriu B. Conti M, et al.
Am J Respir Crit Care Med. 2006; 173(10):1155-1160.
Scherpereel et al, tested a group of 137 patients, in which 74 had malignant pleural mesothelioma (MPM), 35 suffered from pleural metastasis of carcinomas (Mets) and 28 were diagnosed with benign pleural lesions with Asbestos Exposure (BPLAE) from hospitals throughout the northern and western regions of France. The MESOMARK assay (SMRP levels) was used to evaluate serum samples available from this group of patients. The results show a difference in SMRP levels among the three groups, in which the level of SMRP present in patients with MPM was significantly elevated, compared to other evaluated patients. This group concludes that a biomarker to help monitor disease will be a useful tool for physicians. The results of this study clearly show that SMRP values are raised significantly in patients
diagnosed with MPM.